23andMe and Genentech Expand Cancer Study

Last year 23andMe and Genentech launched an online study of metastatic breast cancer to learn more about what role genes might play in how a person responds to bevacizumab, also known as Avastin®. (Avastin® is not approved by the FDA for treatment of metastatic breast cancer.)

We were happy with the positive response from metastatic breast cancer patients, and are excited to announce that Genentech and 23andMe are expanding the eligibility requirements for this research. Starting today, the InVite study is open to any patient in the U.S. who used Avastin prior to 2013 for treatment of metastatic colorectal cancer, metastatic non-squamous non-small cell lung cancer, relapsed glioblastoma, metastatic renal cell carcinoma, or metastatic breast cancer.

Our goal is to recruit 1,000 people to participate in this study. InVite study participants will be asked to send a saliva sample for genetic analysis and to complete up to five short online surveys over the course of a year about their cancer as well as their experience with Avastin. Participants also have the opportunity to provide an optional blood sample for additional analyses.

How you can help

If you have been diagnosed with one of these advanced cancers and have been treated with Avastin prior to 2013, please consider joining the InVite Study. If you know someone who is eligible, please help spread the word about this innovative study: link to find out more.

For more information about the InVite study email invite-study@23andme.com.

By combining participants’ genetic data with survey responses, we hope to discover new genetic markers for these advanced diseases, and to understand why some people respond well to treatment when others do not. 23andMe is excited about partnering with Genentech on this new and innovative web-based approach to data collection and research process.

(While this study may generate important scientific findings, participants should not expect that these findings will change how they are or have been treated for their disease.)

 We appreciate the strong partnerships of breast cancer advocacy groups that have supported and raised awareness for the InVite Study over the last year. These groups include the Avon Foundation for Women, BreastCancer.Org, Living Beyond Breast Cancer, the Metastatic Breast Cancer Network, the Triple Negative Breast Cancer Foundation, the Cancer Support Community, Facing Our Risk for Cancer Empowered (FORCE), EmpowHER, and Stand Up To Cancer. As we expand the study, we are excited to announce new partnerships with the Kidney Cancer Association, LUNGevity, Fight Colorectal Cancer, National Lung Cancer Partnership, Colon Cancer Alliance, and the Musella Foundation.

 


  • margaret duesbury

    why do you not give info for the SNPs relating to increased risk for peripheral neuropathy (“Hand-foot syndrome”) related to chemotherapy – specifically with docetaxol/Paclitaxel/taxanes? I remember there was research regarding markers for this condition about 2-3 years ago, which 25% of the popultation possessed, but I cannot remember the name of the genes affected. Looking at PubMed just now I have found some info on genes RWDD3 and TECTA -but there appears to be a problem with lack of reproducability with these findings. Also found association with FGD4 (rs10771973) ?

Return to top